Moreover, inclisiran, a novel siRNA-based PCSK9 silencer, has recently been approved by the EMA and FDA and has been proven to reduce LDL-C among patients at high risk of cardiovascular diseases (Cicero et al., 2022[13]; Ray et al., 2017[47]). The gene discussed is PCSK9; the disease is cardiovascular disorder.